Leukemia

Papers
(The H4-Index of Leukemia is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms1139
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms950
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia802
COVID-19 in persons with haematological cancers328
MDM2 inhibition: an important step forward in cancer therapy193
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus182
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis177
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation175
SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells165
Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?154
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis146
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances145
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey139
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia135
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments120
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia112
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis106
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression104
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies101
Molecular biology of Hodgkin lymphoma100
Risk factors for death in 1859 subjects with COVID-1996
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)95
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms94
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking93
Hematological features of persons with COVID-1991
Advances in understanding of angioimmunoblastic T-cell lymphoma84
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma79
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia76
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network75
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies73
Therapeutic implications of menin inhibition in acute leukemias72
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia72
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML72
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In70
Treatment and unmet needs in steroid-refractory acute graft-versus-host disease70
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leuk70
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?68
The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis68
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials67
Development of CAR-T cell therapies for multiple myeloma67
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma66
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib66
COVID-19 in persons with chronic myeloid leukaemia65
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab65
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical deci63
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years62
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma61
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 960
Base-edited CAR T cells for combinational therapy against T cell malignancies60
Catch me if you can: how AML and its niche escape immunotherapy60
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia60
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study59
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia59
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment58
Genome instability in multiple myeloma58
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape58
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)57
0.038452863693237